Recent advances in the use of cell-penetrating peptides for medical and biological applications

被引:504
作者
Fonseca, Sonali B. [1 ]
Pereira, Mark P. [1 ]
Kelley, Shana O. [1 ,2 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 1A1, Canada
[2] Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A1, Canada
关键词
Drug delivery; Cell penetrating peptides; HUMAN IMMUNODEFICIENCY VIRUS; SMALL-MOLECULE INHIBITORS; BREAST-CANCER CELLS; IN-VIVO; DRUG-DELIVERY; MULTIDRUG-RESISTANCE; NUCLEIC-ACIDS; LIVING CELLS; TAT PROTEIN; PHOTOCHEMICAL INTERNALIZATION;
D O I
10.1016/j.addr.2009.06.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The selective permeability of the plasma membrane prohibits most exogenous agents from gaining cellular access. Since many therapeutics and reporter molecules must be internalized for activity, crossing the plasma membrane is essential. A very effective class of transporters harnessed for this purpose are cell penetrating peptides (CPPs), a group of short cationic sequences with a remarkable capacity for membrane translocation. Since their discovery in 1988, CPPs have been employed for the delivery of a wide variety of cargo including small molecules, nucleic acids, antibodies and nanoparticles. This review describes recent advances in the use of CPPs for biological and therapeutic applications. In particular, an emphasis is placed on novel systems and insights acquired since 2006. Basic research on CPPs has recently yielded techniques that provide further information on the controversial mechanism of CPP uptake and has also resulted in the development of new model membrane systems to evaluate these mechanisms. In addition, recent use of CPPs for the development of new cellular imaging tools, biosensors, or biomolecular delivery systems have been highlighted. Lastly, novel peptide delivery vectors, designed to tackle some of the drawbacks of CPPs and enhance their versatility, will be described. This review will illustrate the diverse applications for which CPPs have been harnessed and also demonstrate the remarkable advancements these peptides have facilitated in cell biology. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:953 / 964
页数:12
相关论文
共 124 条
[1]   Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies [J].
Abes, Rachida ;
Moulton, Hong M. ;
Clair, Philippe ;
Yang, Sung-Tae ;
Abes, Said ;
Melikov, Kamran ;
Prevot, Paul ;
Youngblood, Derek S. ;
Iversen, Patrick L. ;
Chernomordik, Leonid V. ;
Lebleu, Bernard .
NUCLEIC ACIDS RESEARCH, 2008, 36 (20) :6343-6354
[2]   Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents [J].
Abes, Said ;
Moulton, Hong M. ;
Clair, Philippe ;
Prevot, Paul ;
Youngblood, Derek S. ;
Wu, Rebecca P. ;
Iversen, Patrick L. ;
Lebleu, Bernard .
JOURNAL OF CONTROLLED RELEASE, 2006, 116 (03) :304-313
[3]  
Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2
[4]   TUMOR-CELL RETENTION OF ANTIBODY FAB FRAGMENTS IS ENHANCED BY AN ATTACHED HIV TAT PROTEIN-DERIVED PEPTIDE [J].
ANDERSON, DC ;
NICHOLS, E ;
MANGER, R ;
WOODLE, D ;
BARRY, M ;
FRITZBERG, AR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 194 (02) :876-884
[5]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[6]   Novel Rath peptide for intracellular delivery of protein and nucleic acids [J].
Bais, Manish V. ;
Kumar, Satish ;
Tiwari, Ashok K. ;
Kataria, Ranjit S. ;
Nagaleekar, Viswas K. ;
Shrivastava, Sameer ;
Chindera, Kantaraja .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 370 (01) :27-32
[7]   p14ARF links the tumour suppressors RB and p53 [J].
Bates, S ;
Phillips, AC ;
Clark, PA ;
Stott, F ;
Peters, G ;
Ludwig, RL ;
Vousden, KH .
NATURE, 1998, 395 (6698) :124-125
[8]   Pharmacokinetics and biodistribution of genetically engineered antibodies [J].
Batra, SK ;
Jain, M ;
Wittel, UA ;
Chauhan, SC ;
Colcher, D .
CURRENT OPINION IN BIOTECHNOLOGY, 2002, 13 (06) :603-608
[9]   Protein delivery using VP22 [J].
Bennett, RP ;
Dalby, B .
NATURE BIOTECHNOLOGY, 2002, 20 (01) :20-20
[10]  
Berclaz G, 2001, INT J ONCOL, V19, P1155